HelixGAN a Deep-learning Methodology for Conditional De Novo Design of α-helix Structures
Overview
Authors
Affiliations
Motivation: Protein and peptide engineering has become an essential field in biomedicine with therapeutics, diagnostics and synthetic biology applications. Helices are both abundant structural feature in proteins and comprise a major portion of bioactive peptides. Precise design of helices for binding or biological activity is still a challenging problem.
Results: Here, we present HelixGAN, the first generative adversarial network method to generate de novo left-handed and right-handed alpha-helix structures from scratch at an atomic level. We developed a gradient-based search approach in latent space to optimize the generation of novel α-helical structures by matching the exact conformations of selected hotspot residues. The designed α-helical structures can bind specific targets or activate cellular receptors. There is a significant agreement between the helix structures generated with HelixGAN and PEP-FOLD, a well-known de novo approach for predicting peptide structures from amino acid sequences. HelixGAN outperformed RosettaDesign, and our previously developed structural similarity method to generate D-peptides matching a set of given hotspots in a known L-peptide. As proof of concept, we designed a novel D-GLP1_1 analog that matches the conformations of critical hotspots for the GLP1 function. MD simulations revealed a stable binding mode of the D-GLP1_1 analog coupled to the GLP1 receptor. This novel D-peptide analog is more stable than our previous D-GLP1 design along the MD simulations. We envision HelixGAN as a critical tool for designing novel bioactive peptides with specific properties in the early stages of drug discovery.
Availability And Implementation: https://github.com/xxiexuezhi/helix_gan.
Supplementary Information: Supplementary data are available at Bioinformatics online.
Advance in peptide-based drug development: delivery platforms, therapeutics and vaccines.
Xiao W, Jiang W, Chen Z, Huang Y, Mao J, Zheng W Signal Transduct Target Ther. 2025; 10(1):74.
PMID: 40038239 PMC: 11880366. DOI: 10.1038/s41392-024-02107-5.
An outlook on structural biology after AlphaFold: tools, limits and perspectives.
Rosignoli S, Pacelli M, Manganiello F, Paiardini A FEBS Open Bio. 2024; 15(2):202-222.
PMID: 39313455 PMC: 11788754. DOI: 10.1002/2211-5463.13902.
Qureshi S, Ahmed N, Rehman H, Amirzada M, Saleem F, Waheed K In Silico Pharmacol. 2024; 12(2):84.
PMID: 39301086 PMC: 11408464. DOI: 10.1007/s40203-024-00252-x.
Medina-Ortiz D, Contreras S, Fernandez D, Soto-Garcia N, Moya I, Cabas-Mora G Int J Mol Sci. 2024; 25(16).
PMID: 39201537 PMC: 11487388. DOI: 10.3390/ijms25168851.
Goles M, Daza A, Cabas-Mora G, Sarmiento-Varon L, Sepulveda-Yanez J, Anvari-Kazemabad H Brief Bioinform. 2024; 25(4).
PMID: 38856172 PMC: 11163380. DOI: 10.1093/bib/bbae275.